The DOI matches its Crossref record; 214 of the 214 references it cites were found in a registry or an index.
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Open accessAbstract
Heart failure (HF) has been recognized as a common complication of diabetes, with a prevalence of up to 22% in individuals with diabetes and increasing incidence rates. Data also suggest that HF may develop in individuals with diabetes even in the absence of hypertension, coronary heart disease, or valvular heart disease and, as such, represents a major cardiovascular complication in this vulnerable population; HF may also be the first presentation of cardiovascular disease in many individuals with diabetes. Given that during the past decade, the prevalence of diabetes (particularly type 2 diabetes) has risen by 30% globally (with prevalence expected to increase further), the burden of HF on the health care system will continue to rise. The scope of this American Diabetes Association consensus report with designated representation from the American College of Cardiology is to provide clear guidance to practitioners on the best approaches for screening and diagnosing HF in individuals with diabetes or prediabetes, with the goal to ensure access to optimal, evidence-based management for all and to mitigate the risks of serious complications, leveraging prior policy statements by the American College of Cardiology and American Heart Association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citationEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationLong-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“with results not suggestive of an outcomes benefit (151,152).”
Background2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.007 · Cited by 2,164
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
Tang, A. S. L., Wells, G. A., Talajic, M., Arnold, M. O., Sheldon, R., Connolly, S., Hohnloser, S. H., Nichol, G., Birnie, D. H., Sapp, J. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009540 · Cited by 1,859
Pieske, B., Tschöpe, C., de Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E., Edelmann, F., Fu, M., Guazzi, M., Lam, C. S. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz641 · Cited by 1,855
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.054 · Cited by 1,854
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814 · cited 7×
“In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, in 5,734 individuals with CKD and T2D, it was determined that treatment with finerenone resulted in lower risks of DKD progression and cardiovascular events, myocardial infarction, and hospitalization f…”
BackgroundInfluentialCombination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773
Social determinants of health and diabetes: A scientific review
Hill-Briggs, F., Adler, N. E., Berkowitz, S. A., Chin, M. H., Gary-Webb, T. L., Navas-Acien, A., Thornton, P. L., & Haire-Joshu, D. (2021) · Diabetes Care · doi:10.2337/dci20-0053 · Cited by 1,732
Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2115 · Cited by 1,665
Self-citationCardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.15.1967 · Cited by 1,499
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Vericiguat in patients with heart failure and reduced ejection fraction
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915928 · Cited by 1,358
Reddy, Y. N. V., Carter, R. E., Obokata, M., Redfield, M. M., & Borlaug, B. A. (2018) · Circulation · doi:10.1161/circulationaha.118.034646 · Cited by 1,278
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
He, J., Ogden, L. G., Bazzano, L. A., Vupputuri, S., Loria, C., & Whelton, P. K. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.7.996 · Cited by 1,172 · cited 1×
“Results of several longitudinal observational studies of population-based cohorts with diabetes and prediabetes, including Framingham Heart Study (8), First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-up Study (9), Reykjavik Study (10), and the Scottish diabetes mellitus register (…”
BackgroundSmith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.824 · Cited by 910
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Molecular mechanisms of diabetic cardiomyopathy
Bugger, H., & Abel, E. D. (2014) · Diabetologia · doi:10.1007/s00125-014-3171-6 · Cited by 903
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Maddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., Masoudi, F. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.022 · Cited by 842
Self-citation2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.009 · Cited by 820
Introduction: Standards of Medical Care in Diabetes—2022
American Diabetes Association (2022) · Diabetes Care · doi:10.2337/dc22-sint · Cited by 807
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M. R., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 784
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., Deal, B. J., Dickfeld, T., Field, M. E., Fonarow, G. C., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000549 · Cited by 724
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676 · cited 2×
“For all individuals with HF and diabetes, minimizing alcohol intake and avoidance of smoking (2,77) are recommended.”
BackgroundLedwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., Patle, A., et al. (2013) · JAMA · doi:10.1001/jama.2013.7588 · Cited by 664
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Does This Dyspneic Patient in the Emergency Department Have Congestive Heart Failure?
Wang, C. S. (2005) · JAMA · doi:10.1001/jama.294.15.1944 · Cited by 593
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574 · cited 1×
“In the Degludec Cardiovascular Outcomes Trial (DEVOTE) there was no difference in HF events in patients with T2D with high risk for CVD randomized to insulin glargine or insulin degludec (164).”
BackgroundArrigo, M., Jessup, M., Mullens, W., Reza, N., Shah, A. M., Sliwa, K., & Mebazaa, A. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0151-7 · Cited by 574
Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018
Wang, L., Li, X., Wang, Z., Bancks, M. P., Carnethon, M. R., Greenland, P., Feng, Y.-Q., Wang, H., & Zhong, V. W. (2021) · JAMA · doi:10.1001/jama.2021.9883 · Cited by 571
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556
Martens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543 · cited 1×
“T2D (198)—all of whom are at higher risk”
BackgroundSelf-citationSolomon, S. D., Claggett, B., Lewis, E. F., Desai, A., Anand, I., Sweitzer, N. K., O'Meara, E., Shah, S. J., McKinlay, S., Fleg, J. L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 532
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes
Di Carli, M. F., Janisse, J., Ager, J., & Grunberger, G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00166-9 · Cited by 487
Home-Based Cardiac Rehabilitation
Thomas, R. J., Beatty, A. L., Beckie, T. M., Brewer, L. C., Brown, T. M., Forman, D. E., Franklin, B. A., Keteyian, S. J., Kitzman, D. W., Regensteiner, J. G., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.008 · Cited by 472
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466
Self-citationVimalananda, V. G., Gupte, G., Seraj, S. M., Orlander, J., Berlowitz, D., Fincke, B. G., & Simon, S. R. (2015) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x15582108 · Cited by 437
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction
Cohen, J. B., Schrauben, S. J., Zhao, L., Basso, M. D., Cvijic, M. E., Li, Z., Yarde, M., Wang, Z., Bhattacharya, P. T., Chirinos, D. A., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2019.09.009 · Cited by 432
The vulnerable phase after hospitalization for heart failure
Greene, S. J., Fonarow, G. C., Vaduganathan, M., Khan, S. S., Butler, J., & Gheorghiade, M. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.14 · Cited by 406 · cited 1×
“Each hospitalization for HF is associated with 90-day readmission rates and 1-year mortality approaching 30% (202).”
BackgroundHuelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.069 · Cited by 385 · cited 1×
“with T2D) show that more intensive interventions in those with higher levels of natriuretic peptide reduce risk for LV dysfunction, newly diagnosed HF, or HF hospitalization (59,60) (Table 1).”
BackgroundPratley, R. E., Kanapka, L. G., Rickels, M. R., Ahmann, A., Aleppo, G., Beck, R., Bhargava, A., Bode, B. W., Carlson, A., Chaytor, N. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.6928 · Cited by 375
Self-citationThrainsdottir, I. S., Aspelund, T., Thorgeirsson, G., Gudnason, V., Hardarson, T., Malmberg, K., Sigurdsson, G., & Rydén, L. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.612 · Cited by 374
Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta‐analysis
Martindale, J. L., Wakai, A., Collins, S. P., Levy, P. D., Diercks, D., Hiestand, B. C., Fermann, G. J., deSouza, I., & Sinert, R. (2016) · Academic Emergency Medicine · doi:10.1111/acem.12878 · Cited by 368
Kristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002560 · Cited by 359
Anker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051824 · Cited by 352
Self-citationFitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044138 · Cited by 350 · cited 1×
“Recent trials of SGLT2i that included individuals with HFrEF such as Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) (45% with T2D) (108), as well as Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPERORReduced) (50% with T2D) reported s…”
BackgroundEurich, D. T., Weir, D. L., Majumdar, S. R., Tsuyuki, R. T., Johnson, J. A., Tjosvold, L., Vanderloo, S. E., & McAlister, F. A. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000162 · Cited by 341
Hollenberg, S. M., Warner Stevenson, L., Ahmad, T., Amin, V. J., Bozkurt, B., Butler, J., Davis, L. L., Drazner, M. H., Kirkpatrick, J. N., Peterson, P. N., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.001 · Cited by 336
Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
Tran, D. H., & Wang, Z. V. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012673 · Cited by 335
Regensteiner, J. G., Golden, S., Huebschmann, A. G., Barrett-Connor, E., Chang, A. Y., Chyun, D., Fox, C. S., Kim, C., Mehta, N., Reckelhoff, J. F., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000343 · Cited by 334
Management of diabetes and hyperglycaemia in the hospital
Pasquel, F. J., Lansang, M. C., Dhatariya, K., & Umpierrez, G. E. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30381-8 · Cited by 329 · cited 1×
“It is well-known that diabetes and uncontrolled hyperglycemia are common in the hospital setting and are associated with increases in hospital complications, length of stay, and mortality (204).”
BackgroundZaphiriou, A., Robb, S., Murray-Thomas, T., Mendez, G., Fox, K., McDonagh, T., Hardman, S. M. C., Dargie, H. J., & Cowie, M. R. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.01.022 · Cited by 322
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Diabetes in heart failure: prevalence and impact on outcome in the population
From, A. M., Leibson, C. L., Bursi, F., Redfield, M. M., Weston, S. A., Jacobsen, S. J., Rodeheffer, R. J., & Roger, V. L. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.05.024 · Cited by 295 · cited 1×
“cohorts (22) to 34% in pharmacological intervention trials for systolic HF (23–27),”
BackgroundFinerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051898 · Cited by 294 · cited 1×
“In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial, in 5,734 individuals with CKD and T2D, it was determined that treatment with finerenone resulted in lower risks of DKD progression and cardiovascular events, myocardial infarction, and hospitalization f…”
BackgroundLind, M., Bounias, I., Olsson, M., Gudbjörnsdottir, S., Svensson, A.-M., & Rosengren, A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60471-6 · Cited by 292
Ohkuma, T., Komorita, Y., Peters, S. A. E., & Woodward, M. (2019) · Diabetologia · doi:10.1007/s00125-019-4926-x · Cited by 279
Salzwedel, A., Jensen, K., Rauch, B., Doherty, P., Metzendorf, M.-I., Hackbusch, M., Völler, H., Schmid, J.-P., & Davos, C. H. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320905719 · Cited by 274
Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes
Farkouh, M. E., Domanski, M., Dangas, G. D., Godoy, L. C., Mack, M. J., Siami, F. S., Hamza, T. H., Shah, B., Stefanini, G. G., Sidhu, M. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.001 · Cited by 268
Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure: The ESCAPE Trial
Drazner, M. H., Hellkamp, A. S., Leier, C. V., Shah, M. R., Miller, L. W., Russell, S. D., Young, J. B., Califf, R. M., & Nohria, A. (2008) · Circulation: Heart Failure · doi:10.1161/circheartfailure.108.769778 · Cited by 265
Collins, S. P., Lindsell, C. J., Storrow, A. B., & Abraham, W. T. (2006) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2005.04.003 · Cited by 257
N-Terminal Pro–B-Type Natriuretic Peptide in the Emergency Department
Januzzi, J. L., Chen-Tournoux, A. A., Christenson, R. H., Doros, G., Hollander, J. E., Levy, P. D., Nagurney, J. T., Nowak, R. M., Pang, P. S., Patel, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.021 · Cited by 248
Self-citationMcAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244 · cited 3×
“Results of several longitudinal observational studies of population-based cohorts with diabetes and prediabetes, including Framingham Heart Study (8), First National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-up Study (9), Reykjavik Study (10), and the Scottish diabetes mellitus register (…”
BackgroundHan, M., & Lee, E. (2018) · Healthcare Informatics Research · doi:10.4258/hir.2018.24.3.207 · Cited by 239
Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
Fonarow, G. C., Yancy, C. W., Hernandez, A. F., Peterson, E. D., Spertus, J. A., & Heidenreich, P. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.027 · Cited by 230
McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Self-citationYusuf, S., Ostergren, J. B., Gerstein, H. C., Pfeffer, M. A., Swedberg, K., Granger, C. B., Olofsson, B., Probstfield, J., & McMurray, J. V. (2005) · Circulation · doi:10.1161/circulationaha.104.528166 · Cited by 215
Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., Kolkhof, P., Joseph, A., Mentenich, N., Pitt, B., et al. (2019) · American Journal of Nephrology · doi:10.1159/000503712 · Cited by 214
Doumouras, A. G., Wong, J. A., Paterson, J. M., Lee, Y., Sivapathasundaram, B., Tarride, J.-E., Thabane, L., Hong, D., Yusuf, S., & Anvari, M. (2021) · Circulation · doi:10.1161/circulationaha.120.052386 · Cited by 209
Coronary microvascular dysfunction in hypertrophy and heart failure
Camici, P. G., Tschöpe, C., Di Carli, M. F., Rimoldi, O., & Van Linthout, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa023 · Cited by 203
Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs153 · Cited by 202
Cardiovascular Disease and Homelessness
Baggett, T. P., Liauw, S. S., & Hwang, S. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.077 · Cited by 199
15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s015 · Cited by 197
Greenberg, B. H., Abraham, W. T., Albert, N. M., Chiswell, K., Clare, R., Stough, W. G., Gheorghiade, M., O'Connor, C. M., Sun, J. L., Yancy, C. W., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.001 · Cited by 196
Castagno, D., Baird-Gunning, J., Jhund, P. S., Biondi-Zoccai, G., MacDonald, M. R., Petrie, M. C., Gaita, F., & McMurray, J. J. V. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.030 · Cited by 190
Matsushita, K., Blecker, S., Pazin-Filho, A., Bertoni, A., Chang, P. P., Coresh, J., & Selvin, E. (2010) · Diabetes · doi:10.2337/db10-0165 · Cited by 183
Tromp, J., Tay, W. T., Ouwerkerk, W., Teng, T.-H. K., Yap, J., MacDonald, M. R., Leineweber, K., McMurray, J. J. V., Zile, M. R., Anand, I. S., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002541 · Cited by 180
Vardeny, O., Claggett, B., Kachadourian, J., Desai, A. S., Packer, M., Rouleau, J., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1402 · Cited by 174
Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality
Núñez, J., Bayés-Genís, A., Zannad, F., Rossignol, P., Núñez, E., Bodí, V., Miñana, G., Santas, E., Chorro, F. J., Mollar, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030576 · Cited by 172
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
Sympathetic dysfunction in type 1 diabetes
Pop-Busui, R., Kirkwood, I., Schmid, H., Marinescu, V., Schroeder, J., Larkin, D., Yamada, E., Raffel, D. M., & Stevens, M. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.033 · Cited by 170
Self-citationTaking Diabetes to Heart—Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
Bayeva, M., Sawicki, K. T., & Ardehali, H. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000433 · Cited by 170
Women and Heart Disease: The Role of Diabetes and Hyperglycemia
Barrett-Connor, E., Giardina, E.-G. V., Gitt, A. K., Gudat, U., Steinberg, H. O., & Tschoepe, D. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.934 · Cited by 169
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
Ferreira, J. P., Zannad, F., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Jamal, W., Steubl, D., Schueler, E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.044 · Cited by 165
McGuire, D. K., Alexander, J. H., Johansen, O. E., Perkovic, V., Rosenstock, J., Cooper, M. E., Wanner, C., Kahn, S. E., Toto, R. D., Zinman, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038352 · Cited by 164
Echouffo-Tcheugui, J. B., Xu, H., DeVore, A. D., Schulte, P. J., Butler, J., Yancy, C. W., Bhatt, D. L., Hernandez, A. F., Heidenreich, P. A., & Fonarow, G. C. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.025 · Cited by 160
Anker, S. D., Butler, J., Filippatos, G. S., Khan, M. S., Ferreira, J. P., Bocchi, E. A., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2064 · Cited by 156
Self-citationMcMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Greene, T., Held, C., Hou, F. F., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051675 · Cited by 152
Trends in food insecurity for adults with cardiometabolic disease in the United States: 2005-2012
Berkowitz, S. A., Berkowitz, T. S. Z., Meigs, J. B., & Wexler, D. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179172 · Cited by 147
Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes
Pandey, A., Vaduganathan, M., Patel, K. V., Ayers, C., Ballantyne, C. M., Kosiborod, M. N., Carnethon, M., DeFilippi, C., McGuire, D. K., Khan, S. S., et al. (2021) · JACC: Heart Failure · doi:10.1016/j.jchf.2020.10.013 · Cited by 144 · cited 1×
“Specific to individuals with diabetes, measurement of natriuretic peptides (B-type natriuretic peptide [BNP]; N-terminal pro-BNP [NT-proBNP]) or high-sensitivity cardiac troponin is particularly helpful to identify stage B HF and predict progression to symptoms or death from HF (55,56) (Table 1).”
BackgroundSacre, J. W., Franjic, B., Jellis, C. L., Jenkins, C., Coombes, J. S., & Marwick, T. H. (2010) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2010.09.014 · Cited by 123
Marso, S. P., Baeres, F. M. M., Bain, S. C., Goldman, B., Husain, M., Nauck, M. A., Poulter, N. R., Pratley, R. E., Thomsen, A. B., & Buse, J. B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.063 · Cited by 118
The Future of Heart Failure Diagnosis, Therapy, and Management
Udelson, J. E., & Stevenson, L. W. (2016) · Circulation · doi:10.1161/circulationaha.116.023518 · Cited by 113
Gantz, I., Chen, M., Suryawanshi, S., Ntabadde, C., Shah, S., O’Neill, E. A., Engel, S. S., Kaufman, K. D., & Lai, E. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0593-8 · Cited by 112
AlZadjali, M. A., Godfrey, V., Khan, F., Choy, A. M., Doney, A. S. F., Wong, A., Petrie, J. R., Struthers, A. D., & Lang, C. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.081 · Cited by 106
Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes
Lind, M., Olsson, M., Rosengren, A. H., Svensson, A., Bounias, I., & Guðbjörnsdóttir, S. (2012) · Diabetologia · doi:10.1007/s00125-012-2681-3 · Cited by 105
Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
Januzzi, J. L., Xu, J., Li, J., Shaw, W., Oh, R., Pfeifer, M., Butler, J., Sattar, N., Mahaffey, K. W., Neal, B., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.004 · Cited by 97
Self-citationThomas, K. L., Hernandez, A. F., Dai, D., Heidenreich, P. A., Fonarow, G. C., Peterson, E. D., & Yancy, C. W. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.012 · Cited by 97
Roumie, C. L., Min, J. Y., McGowan, L. D., Presley, C. A., Grijalva, C. G., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Elasy, T. A., & Griffin, M. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005379 · Cited by 97
Swoboda, P., McDiarmid, A. K., Erhayiem, B., Ripley, D. P., Dobson, L. E., Garg, P., Musa, T. A., Witte, K. K., Kearney, M. T., Barth, J. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005539 · Cited by 96
Rosengren, A., Vestberg, D., Svensson, A., Kosiborod, M., Clements, M. A., Rawshani, A., Pivodic, A., Guðbjörnsdóttir, S., & Lind, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00292-2 · Cited by 91
Association Between Cardiovascular Autonomic Neuropathy and Left Ventricular Dysfunction
Pop-Busui, R., Cleary, P. A., Braffett, B. H., Martin, C. L., Herman, W. H., Low, P. A., Lima, J. A. C., & Bluemke, D. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.028 · Cited by 88
Self-citationHow well can the chest radiograph diagnose left ventricular dysfunction?
Badgett, R. G., Mulrow, C. D., Otto, P. M., & Ramírez, G. (1996) · Journal of General Internal Medicine · doi:10.1007/bf02599031 · Cited by 86
CHARM Investigators and Committees, Kristensen, S. L., Jhund, P. S., Lee, M. M. Y., Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6754-x · Cited by 83
Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure
Witte, K. K., Patel, P. A., Walker, A. M., Schechter, C. B., Drozd, M., Sengupta, A., Byrom, R. J., Kearney, L. C., Sapsford, R. J., Kearney, M. T., et al. (2018) · Heart · doi:10.1136/heartjnl-2017-312539 · Cited by 82
von Scholten, B. J., Hasbak, P., Christensen, T. E., Ghotbi, A. A., Kjær, A., Rossing, P. R., & Hansen, T. W. (2015) · Diabetologia · doi:10.1007/s00125-015-3799-x · Cited by 80
Inzucchi, S. E., Docherty, K. F., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Solomon, S. D., Verma, S., Bělohlávek, J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1675 · Cited by 80
Preiss, D., van Veldhuisen, D. J., Sattar, N., Krum, H., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., Pitt, B., Zannad, F., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs067 · Cited by 79
Communication and Interprofessional Collaboration in Primary Care: From Ideal to Reality in Practice
Fox, S., Gaboury, I., Chiocchio, F., & Vachon, B. (2019) · Health Communication · doi:10.1080/10410236.2019.1666499 · Cited by 79
Komajda, M., Tavazzi, L., Francq, B. G., Böhm, M., Borer, J. S., Ford, I., & Swedberg, K. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.347 · Cited by 76 · cited 1×
“Ivabradine is recommended for use in those with HFrEF, in sinus rhythm with resting heart rate $70 bpm, and receiving maximally tolerated b-blocker to reduce the risk of HF hospitalization (114).”
BackgroundPiette, J. D., Rosland, A.-M. M., Marinec, N. S., Striplin, D., Bernstein, S. J., & Silveira, M. J. (2012) · Medical Care · doi:10.1097/mlr.0b013e318277ebf8 · Cited by 74
Khan, M. S., Khan, F., Fonarow, G. C., Sreenivasan, J., Greene, S. J., Khan, S. U., Usman, M., Vaduganathan, M., Fudim, M., Anker, S. D., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2278 · Cited by 74
Brooks, M. M., Chaitman, B. R., Nesto, R. W., Hardison, R. M., Feit, F., Gersh, B. J., Krone, R. J., Sako, E. Y., Rogers, W. J., Garber, A. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.092973 · Cited by 70 · cited 1×
“reduced left ventricular function (193,196).”
Microvascular Disease and Small-Vessel Disease: The Nexus of Multiple Diseases of Women
Patel, H. N., Aggarwal, N. T., Rao, A., Bryant, E., Sanghani, R. M., Byrnes, M., Kalra, D. K., Dairaghi, L., Braun, L. T., Gabriel, S. E., et al. (2020) · Journal of Women s Health · doi:10.1089/jwh.2019.7826 · Cited by 70
Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Johnson, K. C., Pi-Sunyer, X., White, U., Olson, K. L., Bertoni, A. G., Kitzman, D. W., Berry, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050941 · Cited by 69
Accuracy of B-Type Natriuretic Peptide Tests to Exclude Congestive Heart Failure
Battaglia, M., Pewsner, D., Jüni, P., Egger, M., Bucher, H. C., & Bachmann, L. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1073 · Cited by 68
Cooper, L. B., Lippmann, S., Greiner, M. A., Sharma, A., Kelly, J. P., Fonarow, G. C., Yancy, C. W., Heidenreich, P. A., & Hernandez, A. F. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006540 · Cited by 68
Scirica, B. M., D, E. B. M., Raz, I., Cavender, M. A., Morrow, D. A., Jarolı́m, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015511 · Cited by 65
Uijl, A., Koudstaal, S., Vaartjes, I. C. H., Boer, J. M. A., Verschuren, W. M. M., van der Schouw, Y. T., Asselbergs, F. W., Hoes, A. W., & Sluijs, I. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.03.009 · Cited by 62
Wamil, M., Coleman, R. L., Adler, A., McMurray, J. J. V., & Holman, R. R. (2021) · Diabetes Care · doi:10.2337/dc21-0429 · Cited by 61
The importance of physical activity and cardiorespiratory fitness for patients with heart failure
Lindgren, M., & Börjesson, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108833 · Cited by 59
Banks, A. Z., Mentz, R. J., Stebbins, A., Mikus, C. R., Schulte, P. J., Fleg, J. L., Cooper, L. S., Leifer, E. S., Badenhop, D. T., Keteyian, S. J., et al. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.12.007 · Cited by 56 · cited 1×
“compared with those in usual care (84).”
Jarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care · doi:10.2337/dc18-0109 · Cited by 56 · cited 1×
“Furthermore, while one natriuretic peptide or troponin measurement may provide important prognostic insights, serial measurements to detect rising values of either increase sensitivity for identifying those at highest risk for incident HF (57).”
BackgroundBobbio, M., Ferrua, S., Opasich, C., Porcu, M., Lucci, D., Scherillo, M., Tavazzi, L., & Maggioni, A. P. (2003) · Journal of Cardiac Failure · doi:10.1054/jcaf.2003.31 · Cited by 56
Brunvand, L. I., Fugelseth, D., Stensæth, K. H., Dahl‐Jørgensen, K., & Margeirsdottir, H. D. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0288-1 · Cited by 56
Giamouzis, G., Schelbert, E. B., & Butler, J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003259 · Cited by 55
Xie, Y., Bowe, B. C., Gibson, A. K., McGill, J. B., Maddukuri, G. S., & Al‐Aly, Z. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2488 · Cited by 54
Sex Differences in Coronary Microvascular Function in Individuals With Type 2 Diabetes
Haas, A. V., ROSNER, B. A., Kwong, R. Y. K., Rao, A. D., Garg, R., Carli, M. F. D., & Adler, G. K. (2018) · Diabetes · doi:10.2337/db18-0650 · Cited by 52
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors.
Ugusman, A., Kumar, J., & Aminuddin, A. (2021) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2021.107832 · Cited by 52
Martin, D. T., McNitt, S., Nesto, R. W., Rutter, M. K., & Moss, A. J. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.959510 · Cited by 51
Cardiovascular Rehabilitation in Patients With Diabetes
Mourot, L., Boussuges, A., Maunier, S., Chopra, S., Rivière, F., Debussche, X., & Blanc, P. (2010) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e3181c565fe · Cited by 49
Vimalananda, V. G., Dvorin, K., Fincke, B. G., Tardiff, N., & Bokhour, B. G. (2017) · Journal of Ambulatory Care Management · doi:10.1097/jac.0000000000000219 · Cited by 49
Jiménez-Navarro, M. F., López-Jiménez, F. A., Perez-Belmonte, L. M., Lennon, R. J., Diaz-Melean, C. M., Rodríguez-Escudero, J. P., Goel, K., Crusan, D. J., Prasad, A., Squires, R. W., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006404 · Cited by 43
Echouffo-Tcheugui, J. B., Masoudi, F. A., Bao, H., Spatz, E. S., & Fonarow, G. C. (2016) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.116.004132 · Cited by 41
Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization
Gerstein, H. C., Jung, H. J., Rydén, L., Díaz, R., Gilbert, R. E., & Yusuf, S. (2017) · Circulation · doi:10.1161/circulationaha.117.030924 · Cited by 41
Risk of Heart Failure in Patients With Recent-Onset Type 2 Diabetes: Population-Based Cohort Study
Leung, A. A. C., Eurich, D. T., Lamb, D. A., Majumdar, S. R., Johnson, J. A., Blackburn, D. F., & McAlister, F. A. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.004 · Cited by 40
Treatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 37
Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000330 · Cited by 37
Sulfonylureas and Cardiovascular Safety: The Final Verdict?
Wexler, D. J. (2019) · JAMA · doi:10.1001/jama.2019.14533 · Cited by 34
Cited by
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
Self-citation
Metadata
- Authors
- Pop-Busui, R., Januzzi, J. L., Bruemmer, D., Butalia, S., Green, J. B., Horton, W. B., Knight, C., Levi, M., Rasouli, N., & Richardson, C. R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-06-01
- Volume
- 45
- Issue
- 7
- Pages
- 1670-1690
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4281609271
- Cited by
- 399
- References
- 214
- FWCI
- 50.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.